lead drug jakafi initi gain traction
drug approv sever myelofibrosi rare blood disord
jakafi monopoli mf market like continu especi
two lead competitor drug left play field
lacklust pivot trial data expand jakafi label
polycythemia vera late evalu drug
essenti thrombocythemia steroid refractori acut graft
versu host diseas push peak sale
market drug jak inhibitor olumi
baricitinib approv europ rheumatoid arthriti
earli partner
estim ra billion-plu market repres
compel opportun oral treatment like olumi
could support higher treatment penetr rate grow
market oral jak inhibitor xeljanz first market
safeti concern regard seriou infect rate malign
weigh market penetr olumi look slightli
better particular safeti issu though addit black
box label thrombocytosi expect cloud launch
 believ ra market could support multipl jak
inhibitor given high patient churn therapi
compani also robust late-stag pipelin focus primarili
oncolog autoimmun indic provid
attract long-term growth opportun firm
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jun
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
jakafi domin ultra-rare-diseas indic
updat forecast estim jun
face major trial failur believ rest compani
robust pipelin support long-term growth trajectori
use cash gener success jakafi franchis
build suit asset evalu combin
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog drug
iclusig chronic myeloid leukemia pipelin includ broad array
oncolog autoimmun program includ next-gener jak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit jul
margin lower fair valu estim
per share june incorpor
food drug administr approv olumi
baracitinib dose dose propos
eli lilli partner amid safeti concern
unclear safeti data black box warn
thrombocytosi may muddi drug launch result
trim peak sale estim drug
also test autoimmun indic
olumi alreadi approv europ
market receiv royalti
percentag sale addit
develop regulatori mileston project
olumi royalti revenu near million
toward end forecast period also optimist
compani partnership
checkpoint modul program direct gitr
howev yet attribut
valu model enter early-stag
jakafi continu strong perform mf pv
discontinu sanofi mf candid
well lacklust pivot
result gilead momelotinib cti pharma/baxalta
pacritinib believ jakafi near-term growth prospect
improv drug signific first-mov
advantag product could come
think approv jakafi polycythemia vera
potenti label expans essenti thrombocythemia
acut gvhd could lead peak sale billion
next-gener itacitinib could mitig potenti
pipelin gener competit futur
valuat exclud incyt ido inhibitor program light
epacadostat phase trial failur metastat
melanoma combin merck inhibitor
keytruda anticip lacklust result remain
trial evalu epacadostat combin
partnership
astrazeneca bristol would provid upsid fair valu
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum jakafi success
expand indic greater optim
pipelin candid greater oper leverag
result per share fair valu estim
bear-cas scenario model jakafi struggl
penetr mpn market failur earli stage
asset oper cost result signific
financi burden base case result fair
valu drop per share
myeloprolif neoplasm mpn market
includ mf pv merit narrow econom moat rate
firm heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
use patient toler jakafi
low level platelet fail jakafi therapi
near-term prospect promis view mani
early-stag competitor trial way includ
checkpoint inhibitor keytruda opdivo howev
believ earli candid signific
threat incyt jakafi franchis
robust pipelin mitig threat
futur jakafi sale compani sever early-
late-stag candid focus primarili oncolog
inhibitor provid
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin jakafi carv
strong defens market posit
addit label expans pv drug achiev
blockbust statu label expans acut chronic
graft-versus-host-diseas et could boost futur
compani procur candid
immuno-oncolog target posit well
increasingli key therapeut area compani also
sever earlier-stag candid focus primarili
oncolog autoimmun
indic recent
partner checkpoint modul program
direct gitr
opportun remain rel unproven incyt
healthi pipelin give firm margin error believ
strategi develop combin oncolog
regimen bode favor competit advantag
rheumatoid arthriti drug olumi receiv multipl
administr myelofibrosi approv
polycythemia vera refractori patient drug
signific price power first-mov advantag
compet pipelin treatment jakafi solid efficaci
safeti profil patient popul high unmet
need allow compani set averag annual price
world-wide jakafi key patent expir
exclud potenti extens give incyt
signific runway build franchis expand
et gvhd indic
pipelin competit thin recent year
forese signific near-term threat
gilead drug momelotinib cti biopharma/baxalta
drug pacritinib previous led competit
acquisit impact biomedicin earli
celgen reviv anoth competitor program fedratinib
continu believ jakafi set high bar next round
myelofibrosi
novel molecul
lilli inhibitor gandotinib -- expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
setback last fda approv mg
dose mg black box warn due concern
imbal thrombot event treatment
efficaci olumi ra base top-lin
result jak inhibitor xeljanz first
market despit steep competit believ ra
market could support multipl oral jak inhibitor given
high patient churn therapi potenti
near-term catalyst progress dim
time believ uptak ex-u market remain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
jakafi first fda-approv
treatment rare blood disord known
myelofibrosi give strong price power
ojakafi label expans next-gener itacitinib
progress provid near-term catalyst firm
broad array pipelin oncolog
autoimmun program give firm larger margin
error
market upend monopoli
crowd market
thrombocytosi black box warn market
disadvantag
ido inhibitor trial failur melanoma
remov key near-term asset pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end nearli billion cash
market secur limit debt balanc
sheet howev like biotechnolog compani incyt
histor oper loss high cost
clinic trial research loss
financ larg offer equiti debt
secur collabor research develop fund
arrang develop mileston partner
despit heavi spend expect firm
reach sustain profit near term especi
jakafi sale intern royalti off-set
high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent melanoma
trial failur highli anticip ido inhibitor
epacadostat combin merck inhibitor
keytruda also highlight development risk associ
biotech compani furthermor baricitinib
demonstr attract profil conveni oral
formul ra market highli competit
demonstr launch pfizer xeljanz
disappoint even though first oral
product market upadacitinib
demonstr clean safeti profil significantli higher
efficaci drug could give olumi run money
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 market olumi approv less
efficaci mg dose amid concern thrombot event
mg dose
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
govern pension fund norway global
share
fund
share
fund
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
respons research
develop cost entitl substanti royalti
mileston payment although execut
 commerci jakafi well without previou
experi view think would
difficult go alon competit rheumatoid arthriti
market also like manag strategi deploy
cash gener jakafi franchis acquir early-stag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
decreas forecast fve jun
margin lower fair valu estim incyt
per share incorpor food
drug administr approv olumi baracitinib
mg dose mg dose propos
partner amid safeti concern limit approv
par advisori committe recommend
releas earlier april odd approv
dose found elsewher world name europ
japan narrow moat rate remain intact believ
competit advantag rest jakafi franchis
rare blood disord unrel olumi
slightli lower top-lin estim olumi
 market smaller dose could limit usag
drug among sever treatment-refractori patient
could benefit potent mg dose
olumi addit black box warn thrombocytosi
found label incumb jak inhibitor
xeljanz could also temper enthusiasm drug though
lower rel seriou infect malign seen
trial could provid small window opportun incyt
lilli base posit phase result rheumatoid
arthriti popul competitor plan file anoth
oral jak inhibitor upadacitinib fda second
half would posit drug regulatori
decis notabl upadacitinib shown high
efficaci among rheumatoid arthriti patient sign
thrombot event like olumi up-and-com
expect intensifi competit
howev sale outlook alreadi dampen
follow fda complet respons letter
advisori committe mix vote last month addit
believ rheumatoid arthriti market abl
support multipl oral therapi high degre
patient churn differ therapi sinc
receiv portion olumi sale form royalti
partner lilli revis outlook minim
impact valuat rest-of-world sale europ
japan project olumi alreadi gain
approv mg remain unaffect fda limit
olumi news abrupt flash burn
ido inhibitor program believ market
overpen compani creat attract entri
point investor jakafi label expans continu
uptak among approv popul addit
progress next-gener jak inhibitor itacitinib
biggest driver valuat
write incyt ido adcom flop
incyt ido inhibitor flop conflict baracitinib
advisori committe recommend april believ
market over-pen stock first-quart
earn reiter firm prior tribul addit
confirm end nearli late-stag ido
inhibitor studi merck bristol astrazeneca
checkpoint inhibitor expect chang
per share fair valu estim
valuat alreadi exclud futur sale epacadostat
combo incorpor temper baracitinib growth
adjust oper expens fall line
gener jakafi sale provid much-need buffer
allow compani weather two major setback
healthi year-over-year jakafi growth first
quarter rest-of-world sale follow suit underscor
confid franchis narrow econom moat
incyt manag confirm pivot trial test
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
epacadostat combin partner checkpoint
inhibitor halt save two pivot trial
merck keytruda lung cancer convert
fall line decis remov ido combin
sale estim model compani plan
evalu epacadostat non-checkpoint inhibitor
combin variou indic low
expect ido inhibitor class given
direct benefit favor epacadostat found
fail trial stand newlink bristol
larg scrap in-hous ido inhibitor
molecul indoximod respect
reinforc bleak outlook class
despit pessim ido inhibitor still view
ido favor
result
rheumatoid
arthriti patient approv dose threw
salt fresh ido wound howev sale
expect alreadi mute respons fda
complet respons letter lilli first file
believ ra market highli competit
anoth oral jak inhibitor xeljanz market anoth
promis candid work howev
given variou safeti issu surfac among current
risk seriou
infect thrombocytosi well high churn
patient differ therapi believ market
abl support multipl oral drug treatment
decis fda expect june believ
could implic fate baricitinib
immunolog popul said dont
expect launch baricitinib europ
dose alreadi approv olumi
affect regulatori decis
pipelin beyond epacadostat baricitinib still
pack arsen opinion compani expect
file jakafi label expans steroid-refractori acut
graft-versus-host-diseas bodi reject donor
cell transplant back half year fda
approv would expand popul jakafi-elig
patient coupl thousand next-gener jak
inhibitor itacitinib also expect report top-lin data
larger treatment-nav acut graft-versus-host-diseas
next year pivot data bile duct cancer drug
expect second half
conflict adcom vote creat headwind
lilli ra drug share under-valued apr
rheumatoid arthriti drug baricitinib
market olumi europ plan slightli
lower top-lin sale estim drug
expect impact margin neg impact
incyt per share fair valu estim immateri
impact lilli per share fair valu estim
narrow moat rate remain intact base
compani jakafi franchis rare blood cancer
unaffect vote
efficaci once-daili oral baricitinib
mg mg dose acknowledg nearli
unanim vote committe inadequ data rule
safeti imbal name thrombot event
placebo treatment arm ultim led
recommend mg dose reject
risk-benefit profil mg dose lower seriou infect
cancer rate seen baricitinib current
-approv jak inhibitor xeljanz could given
lilli drug edg competitor reach
 market opinion howev baricitinib
unclear safeti result regard thrombot event
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
flag xeljanz trial could muddi advantag
baricitinib member committe note
chanc seriou thrombot event
baricitinib-tr patient actual deviat
incid found gener rheumatoid arthriti
popul howev lack conclus safeti data
sway mani committe member vote toward
recommend mg dose
believ market larg bake sub-optimal
expect baricitinib follow complet respons
letter food drug administr fda
expect drug reach market believ
commerci opportun could constrain
approv label -- recommend dose mg versu
effect mg safeti warn fda
requir follow advisori committe recommend
introduc uncertainti gener fall line
guidanc believ incyt stock still look
under-valued increas interest compani
takeout target level
lower fve ido combo trial
follow-on previou note lower
fair valu estim per share
light epacadostat phase trial failur metastat
melanoma combin merck inhibitor
ido/checkpoint combin fail
improv progression-fre surviv keytruda alon
also appear unlik improv overal surviv
result remov incyt ido inhibitor program
model anticip lacklust result remain
trial evalu epacadostat combin
news major blow compani
believ market fail appreci incyt solid
jakafi franchis robust pipelin strategi beyond ido
program narrow moat rate rest jakafi
strong competit posit price power rare
diseas patient popul unaffect neg ido
underli decis remov futur sale
epacadostat combin model magnitud
trial failur well cautionari commentari
provid manag regard readthrough
ido trial wed stress neg
studi
epacadostat combin keytruda metastat
melanoma would necessarili translat immedi
discount rest incyt ido program across multipl
indic hazard ratio studi leav
direct inkl toward benefit keytruda alon
dampen outlook on-going studi test epacadostat
bristol opdivo astrazeneca imfinzi yet
read posit result could provid upsid
valuat howev optimist especi
manag explicitli call neg
impact probabl success studi
combin epacadostat weve adjust
oper expens account anticip shutter
remain ido program even outsid
melanoma align sg estim
fall line revis guidanc million
put fair valu estim
review adjust model recent disappoint
data ido inhibitor epacadostat weve previous
point epacadostat key driver compani
rate particularli see epacadostat data
on-going phase studi base jakafi entrench
posit myeloprolif neoplasm market
inclin leav narrow moat rate place
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
discuss note last week merck
announc phase studi
epacadostat combin keytruda metastat
melanoma fail combin unabl
improv progression-fre surviv keytruda alon
also unlik improv overal surviv hazard ratio
trend toward benefit compani
halt studi
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
epacadostat failur blow merck
merck announc phase
studi epacadostat combin
keytruda metastat melanoma fail
combin unabl improv progression-fre surviv
keytruda alon unlik improv overal surviv
well hazard ratio trend toward
benefit compani halt studi expect
signific impact fair valu estim
weve previous point epacadostat
key driver compani valuat impact merck
mute compani alreadi establish
leader immuno-oncolog keytruda monotherapi
process launch gather data
combin keytruda variou regimen
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
fve catalyst horizon feb
follow incyt fourth-quart result increas
fair valu estim per share reflect
time valu money updat estim cost
equiti revenu compani jakafi franchis
market jakavi outsid match
thank pipelin progress off-set higher
research develop cost believ incyt jak
inhibitor program includ jakafi next-gener
regimen strong efficaci first-in-class advantag
rare blood disord market uncertainti lead
pivot read-out incyt ido inhibitor drug combin
merck keytruda unfairli weigh compani
share view
total fourth-quart revenu grew year year
driven year-over-year growth jakafi sale
myelofibrosi patient continu major
contributor robust jakafi adopt continu uptak
polycythemia vera patient also tend stay
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rheumatoid arthriti drug baracitinib
incyt intern develop fgfr inhibitor cholangiocarcinoma
type ultra-rar cancer end year believ
bar competitor like upadacitinib
boast similar top-line efficaci increas research
develop forecast reflect grow late-
drug longer provid strong tailwind sequenti
basi jakafi sale roughli flat due announc
inventori stock third quarter despit news
celgen reviv competitor jak program fedratinib
remain confid jak franchis set
high bar new entrant model jakafi sale
toward bottom end manag billion
guidanc higher previou think limit
headwind result updat regul close
donut hole expect impact first-quart growth
although strong new patient demand remain key driver
jakafi sale potenti label expans acut graft-
versus-host-diseas year-end pend posit result
first half year provid anoth near-term
catalyst firm
eye peel upcom pivot result incyt
ido program advanc melanoma expect
first half key driver valuat
trial compar ido/checkpoint inhibitor
combin checkpoint inhibitor monotherapi
believ trial need show compar efficaci
ctla drug regimen margin weaker efficaci coupl
superior safeti profil ctla combin could
also keep ido regimen competit posit
risk neg read-out ido combin
melanoma optimist expect
result believ investor cautiou use
melanoma conclus directli read
rest incyt ido inhibitor program either way
compani sever phase trial evalu
epacadostat combin checkpoint inhibitor
keytruda merck opdivo bristol imfinzi astrazeneca
across number oncolog indic
addit potenti jakafi label expans pivot
epacadostat result anticip two addit catalyst
year includ fda approv eli lilly-partn
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
